Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biogen Idec To Collaborate With Isis On Treatment For Degenerative Muscle Disorder

This article was originally published in The Pink Sheet Daily

Executive Summary

The two companies build on an existing partnership in spinal muscular atrophy to address another muscle-wasting disease. For the second time, they’ve arranged an option deal, with milestones built in both before and after licensing.


Related Content

Isis Builds On Platform Strategy With Fourth Biogen Tie-Up
Business News, In Brief
Isis Teams Up With Roche In Early-Stage Huntington’s Deal
Isis Moves SMA Drug Forward As Market Interest For The Rare Disease Expands
Deals Of The Week: Teva/Xenon, Biogen Idec/Isis, Bristol-Myers Squibb/The Medicines Company
Biogen And Isis Strengthen Their Bond Through Third Tie-Up
Sanofi/Genzyme And Isis Submit Kynamro For Lowering Cholesterol
Biogen Strikes A Deal With Isis For Antisense Technology


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts